Continuous infusion of the alpha 7 nicotinic acetylcholine receptor agonist EVP-6124 produces no signs of tolerance at memory-enhancing doses in rats: a pharmacokinetic and behavioral study

Nick P. van Goethem, Jos Prickaerts, Devin Welty, Dorothy G. Flood, Gerhard Koenig*

*Corresponding author for this work

Research output: Contribution to journalArticleAcademicpeer-review

12 Citations (Web of Science)


We investigated whether the effects of acutely administered EVP-6124, an alpha 7 nicotinic acetylcholine receptor (alpha 7 nAChR) agonist, on cognition were maintained after 6-day continuous minipump administration. Performance in a delay-dependent forgetting test was measured in the object recognition task after single-oral doses of 0.3 or 1 mg/kg, or at plasma steady-state concentrations (C-ss) of 0.6 or 2 ng/ml, which were similar to the efficacious plasma concentrations after single-oral dosing. The 0.3 mg/kg acute dose enhanced memory at a total plasma concentration of similar to 0.3 ng/ml at 1-4 h after dosing. Continuous treatment produced total plasma C-ss values of 0.48 and 1.93 ng/ml on day 6 and enhanced memory. At EVP-6124 plasma concentrations that optimally enhance memory in the object recognition task, tolerance did not develop after 6 days of continuous treatment.
Original languageEnglish
Pages (from-to)403-406
JournalBehavioural Pharmacology
Issue number4
Publication statusPublished - Jun 2015


  • acetylcholine
  • Alzheimer's disease
  • cognition
  • episodic memory
  • EVP-6124
  • object recognition task
  • rat
  • schizophrenia
  • tolerance
  • alpha 7 nAChR agonist

Cite this